A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
- Phone Number: 1-317-615-4559
- Email: clinical_inquiry_hub@lilly.com
Study Locations
-
-
-
Sydney, Australia, 2010
- Holdsworth House Medical Practice
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2010
- East Sydney Doctors
-
Westmead, New South Wales, Australia, 2145
- Westmead Hospital
-
-
Queensland
-
Birtinya, Queensland, Australia, 4575
- Sunshine Coast University Hospital
-
-
Victoria
-
East Melbourne, Victoria, Australia, 3002
- Sinclair Dermatology - East Melbourne
-
Melbourne, Victoria, Australia, 3004
- Alfred Hospital
-
-
Western Australia
-
Fremantle, Western Australia, Australia, 6160
- Fremantle Dermatology
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T3E 0B2
- Beacon Dermatology
-
Edmonton, Alberta, Canada, T6G 1C3
- Alberta Dermasurgery Centre
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3M 3Z4
- Wiseman Dermatology Research Inc.
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada, E3B 1G9
- Brunswick Dermatology Center
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 7G1
- Simcoderm Medical & Surgical Dermatology Centre
-
London, Ontario, Canada, N6H 5L5
- DermEffects - Probity - PPDS
-
-
Quebec
-
Québec, Quebec, Canada, G1W 4R4
- Center de Recherche St Louis
-
-
-
-
-
Berlin, Germany, 10247
- Hautzentrum Friedrichshain - Dermatologie
-
Hamburg, Germany, 20251
- Universitaetsklinikum Hamburg-Eppendorf
-
-
Bavaria
-
Erlangen, Bavaria, Germany, 91054
- Hautklinik Erlangen
-
-
Brandenburg
-
Blankenfelde-Mahlow, Brandenburg, Germany, 15827
- Hautarztpraxis Mahlow
-
-
Hesse
-
Frankfurt am Main, Hesse, Germany, 60596
- Universitätsklinikum Frankfurt
-
-
North Rhine-Westphalia
-
Bochum, North Rhine-Westphalia, Germany, 44791
- Universitaetsklinikum der Ruhr-Universitaet Bochum (UKRUB) - St. Josef-Hospital
-
Bonn, North Rhine-Westphalia, Germany, 53127
- Universitatsklinikum Bonn
-
-
Westfalen
-
Münster, Westfalen, Germany, 48149
- Universitätsklinikum Münster - Albert Schweitzer Campus
-
-
-
-
Attica
-
Athens, Attica, Greece, 16121
- Hospital of Venereal and Skin Diseases A.Syggros
-
-
Irakleío
-
Heraklion, Irakleío, Greece, 711 10
- University General Hospital of Heraklion Loc. 1
-
-
Thessaloníki
-
Thessaloniki, Thessaloníki, Greece, 56429
- Papageorgiou General Hospital of Thessaloniki
-
-
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Poland, 50-566
- Cityclinic Przychodnia Lekarsko Psychologiczna Matusiak Spółka Partnerska
-
Wroclaw, Lower Silesian Voivodeship, Poland, 51-685
- Wro Medica
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Poland, 02-507
- Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Poland, 80-214
- Uniwersyteckie Centrum Kliniczne
-
Malbork, Pomeranian Voivodeship, Poland, 82-200
- Klinika Badawcza Centrum Badan Klinicznych Wojciech Brzezicki
-
-
Silesian Voivodeship
-
Katowice, Silesian Voivodeship, Poland, 40-081
- Centrum Medyczne Pratia Katowice
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Poland, 90-436
- Dermoklinika-Centrum Medyczne s.c
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Medical Dermatology Specialists
-
Phoenix, Arizona, United States, 85008
- Saguaro Dermatology Associates, LLC - Probity - PPDS
-
-
Arkansas
-
North Little Rock, Arkansas, United States, 72117
- Arkansas Research Trials, LLC
-
Rogers, Arkansas, United States, 72758
- Northwest Arkansas Clinical Trials Center
-
-
California
-
Fountain Valley, California, United States, 92708
- First OC Dermatology Research Inc
-
Fremont, California, United States, 94538
- Center for Dermatology Clinical Research, Inc.
-
Los Angeles, California, United States, 90045
- Dermatology Research Associates
-
Santa Monica, California, United States, 90404
- Dermatology Institute and Skin Care Center
-
-
Connecticut
-
Farmington, Connecticut, United States, 06032
- University of Connecticut
-
-
Florida
-
Hialeah, Florida, United States, 33012
- Direct Helpers Research Center
-
Miami, Florida, United States, 33125
- University of Miami
-
Miami, Florida, United States, 33173-1407
- Skin Research of South Florida
-
Tampa, Florida, United States, 33613-1244
- ForCare Clinical Research
-
Tampa, Florida, United States, 33615
- Alliance Clinical Research of Tampa
-
Tampa, Florida, United States, 33615
- Olympian Clinical Research
-
-
Georgia
-
Sandy Springs, Georgia, United States, 30328
- Advanced Medical Research, PC
-
-
Illinois
-
Skokie, Illinois, United States, 60077-1049
- NorthShore Medical Group Dermatology - Skokie
-
-
Indiana
-
Indianapolis, Indiana, United States, 46250
- Dawes Fretzin Clinical Research Group, LLC
-
-
Kentucky
-
Bowling Green, Kentucky, United States, 42104
- Equity Medical - Bowling Green
-
Louisville, Kentucky, United States, 40217
- Derm Research LLC
-
-
Maryland
-
Marriottsville, Maryland, United States, 21104
- Care Access-Marriottsville
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
-
Michigan
-
Troy, Michigan, United States, 48084
- Revival Research Institute - Troy
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Nebraska
-
Omaha, Nebraska, United States, 68144
- Skin Specialists, P.C
-
-
New Hampshire
-
Portsmouth, New Hampshire, United States, 03801
- ActivMed Practices & Research, Inc.
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28277
- Dermatology Specialists of Charlotte
-
Charlotte, North Carolina, United States, 28277-8014
- Darst Dermatology
-
Durham, North Carolina, United States, 27710-3038
- Duke University Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals Cleveland Medical Center
-
Mayfield Heights, Ohio, United States, 44124
- Apex Clinical Research Center
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, United States, 17011
- DermDox Centers for Dermatology
-
Sugarloaf, Pennsylvania, United States, 18249
- DermDox Dermatology Centers
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, United States, 29212-8623
- Columbia Dermatology & Aesthetics
-
-
Tennessee
-
Murfreesboro, Tennessee, United States, 37130
- International Clinical Research - Tennessee (IC Research)
-
Nashville, Tennessee, United States, 37211
- Advanced Research Experts
-
-
Texas
-
Dallas, Texas, United States, 75231
- Modern Research Associates
-
Frisco, Texas, United States, 75034
- North Texas Clinical Research
-
-
Utah
-
South Jordan, Utah, United States, 84095
- Jordan Valley Dermatology Center
-
-
Washington
-
Spokane, Washington, United States, 99202-1332
- Dermatology Specialists of Spokane
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have a diagnosis of HS for at least 12 months.
- Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III.
- Have an (abscess plus inflammatory nodule) count of at least 5.
- Agree to use topical antiseptics daily.
- Had an inadequate response or intolerance to a 28-day course of oral antibiotics.
Exclusion Criteria:
- Have more than 20 draining fistulae.
- Have had surgical treatment for HS in the last 4 weeks before randomization.
- Have an active skin disease or condition, that could interfere with the assessment of HS.
- Have a current or recent acute, active infection.
- Are immunocompromised.
- Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Eltrekibart Dose 1
Eltrekibart will be given subcutaneously (SC).
|
Administered SC
Other Names:
|
|
Experimental: Eltrekibart Dose 2
Eltrekibart will be given SC.
|
Administered SC
Other Names:
|
|
Experimental: Eltrekibart Dose 3
Eltrekibart will be given SC.
|
Administered SC
Other Names:
|
|
Placebo Comparator: Placebo
Placebo will be given.
|
Administered SC
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)
Time Frame: Week 16
|
Week 16
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Mean Change from Baseline in Total Number of Abscesses and Inflammatory Nodules
Time Frame: Baseline, Week 16
|
Baseline, Week 16
|
|
Mean Change from Baseline in HS-related Average Skin Pain Numerical Rating Scale (NRS)
Time Frame: Baseline, Week 16
|
Baseline, Week 16
|
|
Pharmacokinetics (PK): Plasma Concentrations of Eltrekibart
Time Frame: Baseline through Week 16
|
Baseline through Week 16
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Skin Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Sweat Gland Diseases
- Skin Diseases, Bacterial
- Skin Diseases, Infectious
- Suppuration
- Hidradenitis
- Skin and Connective Tissue Diseases
- Hidradenitis Suppurativa
- Substandard Drugs
- Pharmaceutical Preparations
- Counterfeit Drugs
Other Study ID Numbers
Other Study ID Numbers
- 18518
- 2023 (U.S. NIH Grant/Contract: GRAMMY Museum Foundation)
- I7P-MC-DSAF (Other Identifier: Eli Lilly and Company)
- 2023-505608-43-00 (Other Identifier: EU Trial Number)
- U1111-1292-6255 (Other Identifier: UTN Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.